Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Clinical manifestations of Staphylococcus aureus infection

INTRODUCTION

Staphylococcus aureus is a frequent colonizer of the skin and mucosa and can cause a broad range of clinical manifestations, ranging from relatively benign skin infections to life-threatening conditions such as endocarditis and osteomyelitis.

Risk factors for complications of S. aureus infection include community acquisition of infection, presence of prosthetic material [1-6], and underlying medical conditions including immunosuppression [7-12]. Other factors that may predict complications in patients with S. aureus bacteremia include growth of S. aureus within 14 hours following blood culture incubation, positive follow-up blood cultures 48 to 96 hours after admission (odds ratio [OR] 5.58, 95% CI 3.93-7.95), and persistent fever 72 hours after admission (OR 2.23, 95% CI 1.55-3.12) [2,10,13-15].

Patients with community-acquired S. aureus bacteremia have an increased risk for metastatic complications [2,16-20]. In one study including 281 patients with S. aureus bacteremia, metastatic complications were more common among patients with community-acquired rather than hospital-acquired bacteremia (43 versus 21 percent) [18]. The explanation may be related to prolonged duration of bacteremia. In an observational study including 245 patients with S. aureus bacteremia, the complication rate increased with duration of bacteremia (6, 24, and 38 percent in bacteremia for 1 to 2, 3, and ≥4 days, respectively) [21].

The absence of a clinically identifiable source of S. aureus bacteremia is an important predictor of subsequent complications [18,19]. In a series of 281 patients with S. aureus bacteremia, the incidence of a metastatic complication was lower among patients with an identifiable source of bacteremia than among patients without a clear source (21 versus 51 percent, respectively) [18].

The clinical manifestations of S. aureus infection will be reviewed here. The clinical approach to S. aureus bacteremia is discussed separately. (See "Clinical approach to Staphylococcus aureus bacteremia in adults".)

                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Oct 9, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695.
  2. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066.
  3. Chu VH, Crosslin DR, Friedman JY, et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med 2005; 118:1416.
  4. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89:137.
  5. Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670.
  6. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.
  7. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med 1988; 85:172.
  8. Decker CF, Tuazon CU. Staphylococcus aureus pericarditis in HIV-infected patients. Chest 1994; 105:615.
  9. Gunnarsson G, Friedman LS, Wanke C. Liver abscesses due to Staphylococcus aureus in a patient with AIDS who underwent small bowel biopsy: case report and review. Clin Infect Dis 1994; 18:802.
  10. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.
  11. Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007; 86:54.
  12. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000; 18:1110.
  13. Eng RH, Bishburg E, Smith SM, Scadutto P. Staphylococcus aureus bacteremia during therapy. J Infect Dis 1987; 155:1331.
  14. Lesens O, Hansmann Y, Brannigan E, et al. Positive surveillance blood culture is a predictive factor for secondary metastatic infection in patients with Staphylococcus aureus bacteraemia. J Infect 2004; 48:245.
  15. Khatib R, Riederer K, Saeed S, et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 2005; 41:594.
  16. Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis: comparison of nosocomial and community-acquired infection. J Med 1984; 15:193.
  17. Ing MB, Baddour LM, Bayer AS. Bacteremia and infective endocarditis: Pathogenesis, diagnosis, and complications. In: The Staphylococci in Human Disease, Crossley KB, Archer GL (Eds), Churchill Livingstone, New York 1997. p.331.
  18. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16:567.
  19. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med 1976; 60:495.
  20. Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998; 91:41.
  21. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38:7.
  22. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.
  23. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322.
  24. Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15.
  25. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med 1993; 119:560.
  26. El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 2005; 118:225.
  27. Hill EE, Vanderschueren S, Verhaegen J, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin Proc 2007; 82:1165.
  28. Nadji G, Rémadi JP, Coviaux F, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart 2005; 91:932.
  29. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.
  30. Robinson SL, Saxe JM, Lucas CE, et al. Splenic abscess associated with endocarditis. Surgery 1992; 112:781.
  31. Ting W, Silverman NA, Arzouman DA, Levitsky S. Splenic septic emboli in endocarditis. Circulation 1990; 82:IV105.
  32. Johnson JD, Raff MJ, Barnwell PA, Chun CH. Splenic abscess complicating infectious endocarditis. Arch Intern Med 1983; 143:906.
  33. Ebright JR, Alam E, Ahmed H, et al. Splenic infarction and abscess in the setting of infective endocarditis. Infect Dis Clin Pract 2007; 15:17.
  34. Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146:953.
  35. Espersen F, Frimodt-Møller N, Thamdrup Rosdahl V, et al. Changing pattern of bone and joint infections due to Staphylococcus aureus: study of cases of bacteremia in Denmark, 1959-1988. Rev Infect Dis 1991; 13:347.
  36. Murdoch DR, Roberts SA, Fowler Jr VG Jr, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001; 32:647.
  37. Pintado V, Meseguer MA, Fortún J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.
  38. Jensen AG, Espersen F, Skinhøj P, et al. Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch Intern Med 1993; 153:1902.
  39. Lee BK, Crossley K, Gerding DN. The association between Staphylococcus aureus bacteremia and bacteriuria. Am J Med 1978; 65:303.
  40. Sheth S, DiNubile MJ. Clinical significance of staphylococcus aureus bacteriuria without concurrent bacteremia. Clin Infect Dis 1997; 24:1268.
  41. Muder RR, Brennen C, Rihs JD, et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clin Infect Dis 2006; 42:46.
  42. Anderson DJ, Kaye KS, Sexton DJ. Methicillin-resistant Staphylococcus aureus bacteremia after isolation from urine. Clin Infect Dis 2006; 42:1504.
  43. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.
  44. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.
  45. Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.
  46. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050.
  47. Eftychiou C, Samarkos M, Golfinopoulou S, et al. Henoch-Schonlein purpura associated with methicillin-resistant Staphylococcus aureus infection. Am J Med 2006; 119:85.